The company made history by becoming the first healthcare firm to surpass a $1 trillion market capitalization, driven by surging demand for its GLP-1 diabetes and obesity drugs. Multiple analysts have raised price targets significantly, with one firm setting a $1,300 target representing over 20% upside. The stock has surged 29% recently, fueled by optimism about its innovation pipeline, AI-powered developments, manufacturing investments, and the potential of its upcoming oral obesity treatment. The weight-loss drug market is projected to approach $100 billion by 2030.